FierceBiotechOriginal article
{"a":[{"_":"‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong","$":{"href":"/biotech/axiom-plans-head-nasdaq-hong-kong","hreflang":"en"}}]}
IPO/OfferingPositive
AI Analysis
Summary
Axiom Biosciences plans to become the first U.S. biotech to pursue an IPO on the Hong Kong Stock Exchange followed by a Nasdaq co-listing, announcing this unconventional capital raise strategy.
Outcome Details
Company intends to pursue IPO on Hong Kong Stock Exchange followed by co-listing on Nasdaq
Importance:5/10
Sentiment:
0.30
IPOHong Kong Stock ExchangeNasdaqUS biotechcapital raise
Read the original article
Published by FierceBiotech on July 20, 2026 2:41 PM